Advertisement
Canada markets closed

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7301
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    82.68
    -0.13 (-0.16%)
     

  • Bitcoin CAD

    88,370.00
    -3,103.43 (-3.39%)
     

  • CMC Crypto 200

    1,393.30
    -30.80 (-2.16%)
     

  • GOLD FUTURES

    2,329.20
    -9.20 (-0.39%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,482.50
    -182.00 (-1.03%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,913.07
    -547.01 (-1.42%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     

ChemoCentryx: 4Q Earnings Snapshot

Associated Press
Updated ·1 min read

MOUNTAIN VIEW, Calif. (AP) _ ChemoCentryx Inc. (CCXI) on Monday reported a loss of $29.9 million in its fourth quarter.

On a per-share basis, the Mountain View, California-based company said it had a loss of 43 cents.

The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 32 cents per share.

The biopharmaceutical company posted revenue of $4.4 million in the period, which also did not meet Street forecasts. Five analysts surveyed by Zacks expected $8.9 million.

For the year, the company reported that its loss narrowed to $55.4 million, or 84 cents per share. Revenue was reported as $64.9 million.

ADVERTISEMENT

ChemoCentryx shares have climbed 10% since the beginning of the year. In the final minutes of trading on Monday, shares hit $68.40, an increase of 55% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CCXI at https://www.zacks.com/ap/CCXI